582 results The EU Artificial Intelligence Act: our 16 key takeaways The AI Act is the first comprehensive AI regulation in the world. In this first episode of our Artificial Intelligence series, we have set out our initial key takeaways on the AI Act based on the text as currently approved by the Council of the EU. District Court ruled on the recognition of the res judicata effect of a Turkish judgment and dismissed an antitrust follow on damages claim regarding the cathode-ray tube markets The District Court of Oost-Brabant recognized the res judicata effect of a Turkish court of appeal judgment, in which the Turkish court had dismissed antitrust damages claims brought by Vestel against Philips, Samsung, LGE, Technicolor, TTD and TDP. Stibbe advises Goed A multidisciplinary Stibbe team advised Goed and its shareholders on its binding agreement with Mulitpharma relating to the sale of Goed’s pharmaceutical retail and wholesale business. The Commission’s ‘killer’ pharma campaign: reason to complain? The European Commission is on the prowl in the pharma sector. Recent cases on alleged disparagement and pipeline drugs-killings show that it is not afraid to show its teeth and, ultimately, bite. Digital antitrust conduct: too elusive to catch? The ink on the Digital Market Act has barely dried, but fast-evolving digital developments already have competition authorities calling for new tools. Is Big Tech not kept in check by the DMA, the antitrust rules and the EU Merger Regulation after all? The Foreign Subsidies Regulation’s initial focus on China Although the text of the Foreign Subsidies Regulation is not aimed at specific countries, the European Commission’s initial enforcement actions appear to be targeting Chinese subsidies. Third time lucky: Intel wins loyalty rebate battle at EU top court The European Court of Justice has upheld the annulment of Intel’s EUR 1.06 billion fine for abuse of dominance. The judgment provides guidance on how to assess the anti-competitiveness of loyalty rebates. If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug. Tekst & Commentaar Mededingingsrecht Roos Elemans en Jurriaan van Gent droegen bij aan de nieuwe uitgave van Tekst & Commentaar Mededingingsrecht. Mede dankzij deze bijdrage kunnen (mededingings-)juristen actief op het gebied van investeringstoetsingen nu gebruikmaken van dit naslagwerk. Van procederen kun je leren? Rechterlijke toetsing van concentratiezaken in Nederland Roos Elemans en Simone Evans staan in een artikel voor het Tijdschrift Mededingingsrecht in de Praktijk stil bij de vraag: wel of geen beroep instellen tegen een concentratiebesluit? De Europese Commissie, de Staat en de (inter)nationale rechter: een staatssteunrechtelijk 'Game of Thrones' of checks and balances? De staatssteunrechtelijke bevoegdhedenverdeling tussen de Europese Commissie, de Staat en de rechter houdt de gemoederen bezig. Een voorbeeld hiervan biedt de Micula rechtspraak over investeringsarbitrage. Deze blog bespreekt dergelijke zaken. Stibbe Amsterdam appoints three new partners We are pleased to announce that Stibbe Amsterdam has promoted Roos Elemans, Lotte Hover-Boon and Daisy Nijkamp to partner effective 1 January 2025. These appointments will further strengthen our EU and Competition Law, Tax and Litigation practices. EU lift cartel damage claim rejected by Brussels Court of Appeal After 16 years of court battle, the Brussels Court of Appeal has rejected the EU’s EUR 12 million (+ interest) damage claim against the four lift producers that participated in the lift cartel fined in 2007. Mari Muzashvili Junior Associate Brussels Belgian watchdog tackles bid rigging In recent cases in the fire protection and private security sectors, the Belgian Competition Authority has made the prosecution of bid-rigging one of its top priorities, imposing hefty fines on infringers for their participation in cartel schemes. First trip around the sun: FSR – one year in review The Foreign Subsidies Regulation has celebrated one year of its application. Time for companies to take stock of the lessons learnt from key developments of this first year. However, ambiguities remain and more is yet to come. Watch this space! To Prove or Presume? The EC’s Draft Guidelines on exclusionary abuses The Commission recently published its Draft Guidelines on Exclusionary Abuses of Dominance, which are meant to reflect the EU case law. However, they seem to deviate on important aspects, arguably simplifying the assessment for establishing an abuse. FDI screening guidance: shedding some light in the darkness The Dutch general investment screening regime came into effect in June 2023. Decisions are not yet publicly available. However, three guidance papers list the practical experience gained so far and help to assess whether a transaction is notifiable. Pagination Previous page Page 10 Current page 11 Page 12 Page 13 Next page
The EU Artificial Intelligence Act: our 16 key takeaways The AI Act is the first comprehensive AI regulation in the world. In this first episode of our Artificial Intelligence series, we have set out our initial key takeaways on the AI Act based on the text as currently approved by the Council of the EU.
District Court ruled on the recognition of the res judicata effect of a Turkish judgment and dismissed an antitrust follow on damages claim regarding the cathode-ray tube markets The District Court of Oost-Brabant recognized the res judicata effect of a Turkish court of appeal judgment, in which the Turkish court had dismissed antitrust damages claims brought by Vestel against Philips, Samsung, LGE, Technicolor, TTD and TDP.
Stibbe advises Goed A multidisciplinary Stibbe team advised Goed and its shareholders on its binding agreement with Mulitpharma relating to the sale of Goed’s pharmaceutical retail and wholesale business.
The Commission’s ‘killer’ pharma campaign: reason to complain? The European Commission is on the prowl in the pharma sector. Recent cases on alleged disparagement and pipeline drugs-killings show that it is not afraid to show its teeth and, ultimately, bite.
Digital antitrust conduct: too elusive to catch? The ink on the Digital Market Act has barely dried, but fast-evolving digital developments already have competition authorities calling for new tools. Is Big Tech not kept in check by the DMA, the antitrust rules and the EU Merger Regulation after all?
The Foreign Subsidies Regulation’s initial focus on China Although the text of the Foreign Subsidies Regulation is not aimed at specific countries, the European Commission’s initial enforcement actions appear to be targeting Chinese subsidies.
Third time lucky: Intel wins loyalty rebate battle at EU top court The European Court of Justice has upheld the annulment of Intel’s EUR 1.06 billion fine for abuse of dominance. The judgment provides guidance on how to assess the anti-competitiveness of loyalty rebates.
If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.
Tekst & Commentaar Mededingingsrecht Roos Elemans en Jurriaan van Gent droegen bij aan de nieuwe uitgave van Tekst & Commentaar Mededingingsrecht. Mede dankzij deze bijdrage kunnen (mededingings-)juristen actief op het gebied van investeringstoetsingen nu gebruikmaken van dit naslagwerk.
Van procederen kun je leren? Rechterlijke toetsing van concentratiezaken in Nederland Roos Elemans en Simone Evans staan in een artikel voor het Tijdschrift Mededingingsrecht in de Praktijk stil bij de vraag: wel of geen beroep instellen tegen een concentratiebesluit?
De Europese Commissie, de Staat en de (inter)nationale rechter: een staatssteunrechtelijk 'Game of Thrones' of checks and balances? De staatssteunrechtelijke bevoegdhedenverdeling tussen de Europese Commissie, de Staat en de rechter houdt de gemoederen bezig. Een voorbeeld hiervan biedt de Micula rechtspraak over investeringsarbitrage. Deze blog bespreekt dergelijke zaken.
Stibbe Amsterdam appoints three new partners We are pleased to announce that Stibbe Amsterdam has promoted Roos Elemans, Lotte Hover-Boon and Daisy Nijkamp to partner effective 1 January 2025. These appointments will further strengthen our EU and Competition Law, Tax and Litigation practices.
EU lift cartel damage claim rejected by Brussels Court of Appeal After 16 years of court battle, the Brussels Court of Appeal has rejected the EU’s EUR 12 million (+ interest) damage claim against the four lift producers that participated in the lift cartel fined in 2007.
Belgian watchdog tackles bid rigging In recent cases in the fire protection and private security sectors, the Belgian Competition Authority has made the prosecution of bid-rigging one of its top priorities, imposing hefty fines on infringers for their participation in cartel schemes.
First trip around the sun: FSR – one year in review The Foreign Subsidies Regulation has celebrated one year of its application. Time for companies to take stock of the lessons learnt from key developments of this first year. However, ambiguities remain and more is yet to come. Watch this space!
To Prove or Presume? The EC’s Draft Guidelines on exclusionary abuses The Commission recently published its Draft Guidelines on Exclusionary Abuses of Dominance, which are meant to reflect the EU case law. However, they seem to deviate on important aspects, arguably simplifying the assessment for establishing an abuse.
FDI screening guidance: shedding some light in the darkness The Dutch general investment screening regime came into effect in June 2023. Decisions are not yet publicly available. However, three guidance papers list the practical experience gained so far and help to assess whether a transaction is notifiable.